Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Actinic Keratosis
Interventions
DRUG

Imiquimod 3.75% Cream

Approximately two weeks after Day 0, the entire treatment area was treated with imiquimod 3.75% cream. Subjects utilized the 2 weeks on, 2 weeks off, 2 weeks on regimen. Subjects were followed every 2 weeks during treatment (week 2, 4 and 6) and then at 4 and 8 weeks post last-imiquimod application (week 10 and 14).

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
collaborator

Bausch Health Americas, Inc.

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT03914417 - Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream | Biotech Hunter | Biotech Hunter